Want to see ATNM full AI Analyst Report?
ATNM Stock Chart & Stats
$1.30
-$0.06(-4.32%)
At close: 4:00 PM EST
$1.30
-$0.06(-4.32%)
Day’s Range― - ―
52-Week Range$0.88 - $1.89
Previous CloseN/A
Volume63.23K
Average Volume (3M)208.30K
Market Cap
$28.24M
Enterprise Value-$8.61M
Total Cash (Recent Filing)$42.13M
Total Debt (Recent Filing)$1.52M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding31,374,990
10 Day Avg. Volume380,172
30 Day Avg. Volume208,296
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.30
Enterprise Value/Revenue-95.67
Enterprise Value/Gross Profit-17.75
Enterprise Value/Ebitda0.38
Forecast
1Y Price Target
$4.00Price Target Upside207.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Radioconjugate Platform & PipelineActinium’s focused radioconjugate platform and multiple clinical-stage programs create structurally durable R&D optionality. Specialization in targeted radioisotopes for hematologic malignancies and transplant conditioning builds a defensible niche with potential for durable partnerships and licensing across oncology indications.
Preclinical Progress On ATNM-400New preclinical ATNM-400 data across prostate and non-small cell lung cancer models demonstrates platform extensibility beyond AML. Progress reported at a major scientific meeting enhances scientific credibility, strengthens long-term pipeline breadth, and improves prospects for collaborations or follow-on clinical programs.
Low Absolute Debt Provides CushionThe company’s low absolute debt is a durable balance-sheet advantage versus highly levered peers, lowering near-term interest burden and preserving flexibility to raise capital or partner. This structural cushion supports continued clinical development despite cash burn and reduces bankruptcy risk from leverage.
Bears Say
Persistent Cash Burn And Negative Cash FlowSustained negative operating and free cash flow indicates the business consumes real cash to fund R&D, increasing reliance on external financing. Over months, this raises dilution risk, constrains ability to execute multiple trials concurrently, and forces prioritization of programs, limiting strategic optionality.
Ongoing Large Losses And Minimal RevenueThe firm’s multi-year operating losses and negligible revenues reflect a development-stage model without product cash flows. Structurally, this leaves long-term viability dependent on successful clinical outcomes, partnerships, or financing events, making capital access and sustained investment execution uncertain.
NYSE Noncompliance & Materially Low EquityFailure to meet NYSE American equity standards and materially reduced stockholders' equity create a structural listing risk that can impair liquidity and access to public capital. The overhang may force dilutive financings, distract management, and increase execution risk for long-term clinical programs.
Actinium Pharmaceuticals News
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $0.88 and its highest was $1.89 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is $28.24M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 23, 2026 which is in 123 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,374,990 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in ATNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
ATNM Stock 12 Month Forecast
Average Price Target
$4.00
▲(207.69% Upside)
Technical Analysis
InflaRx
―
Gain Therapeutics
―
Unicycive Therapeutics
―
Adlai Nortye Ltd. Sponsored ADR
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
0.59% Insiders
5.49% Mutual Funds
0.10% Other Institutional Investors
89.55% Public Companies and
Individual Investors